Search

Your search keyword '"Schultz, W"' showing total 1,556 results
Start Over Author "Schultz, W"

Refine your results

more »

more »

more »

more »

more »

more »
1,556 results on '"Schultz, W"'

60. Constituents of an organic wood preservative that inhibit the fluoranthene-degrading activity of Sphingomonas paucimobilis strain EPA505

Author

Lantz, S. E., Montgomery, M. T., Schultz, W. W., Pritchard, P. H., Spargo, B. J., and Mueller, J. G.

Subjects
Wood preservatives -- Research, Creosote -- Research, Polycyclic aromatic hydrocarbons -- Research, Phenols -- Research, Biodegradation -- Research, Environmental issues, Science and technology
Abstract

Solvent extraction of organic wood preservative, creosote, yielded three classes of creosote contituents namely polycyclic aromatic hydrocarbons (PAHs), phenolics and heterocyclics, that inhibit the fluoranthene-degrading activity of Sphingomonas paucimobilis strain EPA505. The integration of a pretreatment step prior to inoculation of strain EPA505 could help increase the effectiveness of strain EPA505 to degrade fluoranthene.

Published
1997

73. Using Nonlinearity and Contact Lines to Control Fluid Flow in Microgravity

Author

Perlin, M, Schultz, W. W, Bian, X, and Agarwal, M

Subjects
Space Processing
Abstract

Slug flows in a tube are affected by surface tension and contact lines, especially under microgravity. Numerical analyses and experiments are conducted of slug flows in small-diameter tubes with horizontal, inclined and vertical orientations. A PID-controlled, meter-long platform capable of following specified motions is used. An improved understanding of the contact line boundary condition for steady and unsteady contact-line motion is expected. Lastly, a direct fluid-handling method using nonlinear oscillatory motion of a tube is presented.

Published
2002

80. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial

Author

Thuijs, D. J. F. M., Kappetein, A. P., Serruys, P. W., Mohr, F. -W., Morice, M. -C., Mack, M. J., Holmes, D. R., Curzen, N., Davierwala, P., Noack, T., Milojevic, M., Dawkins, K. D., da Costa, B. R., Juni, P., Head, S. J., Casselman, F., de Bruyne, B., Hoj Christiansen, E., Ruiz-Nodar, J. M., Vermeersch, P., Schultz, W., Sabatelli, Mario, Guagliumi, G., Grubitzsch, H., Stangl, K., Darremont, O., Bentala, M., den Heijer, P., Preda, I., Stoler, R., Szerafin, T., Buckner, J. K., Guber, M. S., Verberkmoes, N., Akca, F., Feldman, T., Beyersdorf, F., Drieghe, B., Oldroyd, K., Berger, Gerit, Jeppsson, A., Barber, K., Wolschleger, K., Heiser, J., van der Harst, P., Mariani, M. A., Reichenspurner, H., Stark, C., Laineri Milazzo, Marco, Ho, P. C., Chen, J. C., Zelman, R., Horwitz, P. A., Bochenek, A., Krauze, A., Grothusen, C., Dudek, D., Heyrich, G., Kolh, P., Legrand, V., Coelho, P., Ensminger, S., Nasseri, B., Ingemansson, R., Olivecrona, G., Escaned, J., Guera, R., Berti, S., Chieffo, A., Burke, N., Mooney, M., Spolaor, A., Hagl, C., Nabauer, M., Suttorp, M. J., Stine, R. A., Mcgarry, T., Lucas, S., Endresen, K., Taussig, A., Accola, K., Canosi, U., Horvath, I., Cannon, L., Talbott, J. D., Akins, C. W., Kramer, R., Aschermann, M., Killinger, W., Narbute, I., Burzotta, Francesco, Bogers, A., Zijlstra, F., Eltchaninoff, H., Berland, J., Stefanini, G., Cruz Gonzalez, I., Hoppe, U., Kiesz, S., Gora, B., Ahlsson, A., Corbascio, M., Bilfinger, T., Carrie, D., Tchetche, D., Hauptman, K. -E., Stahle, E., James, S., Sandner, S., Laufer, G., Lang, I., Witkowski, A., Thourani, V., Suryapranata, H., Redwood, S., Knight, C., Maccarthy, P., de Belder, A., Banning, A., Gershlick, A., Sabate M. (ORCID:0000-0001-6635-4985), Berg G., Laine M., Burzotta F. (ORCID:0000-0002-6569-9401), Thuijs, D. J. F. M., Kappetein, A. P., Serruys, P. W., Mohr, F. -W., Morice, M. -C., Mack, M. J., Holmes, D. R., Curzen, N., Davierwala, P., Noack, T., Milojevic, M., Dawkins, K. D., da Costa, B. R., Juni, P., Head, S. J., Casselman, F., de Bruyne, B., Hoj Christiansen, E., Ruiz-Nodar, J. M., Vermeersch, P., Schultz, W., Sabatelli, Mario, Guagliumi, G., Grubitzsch, H., Stangl, K., Darremont, O., Bentala, M., den Heijer, P., Preda, I., Stoler, R., Szerafin, T., Buckner, J. K., Guber, M. S., Verberkmoes, N., Akca, F., Feldman, T., Beyersdorf, F., Drieghe, B., Oldroyd, K., Berger, Gerit, Jeppsson, A., Barber, K., Wolschleger, K., Heiser, J., van der Harst, P., Mariani, M. A., Reichenspurner, H., Stark, C., Laineri Milazzo, Marco, Ho, P. C., Chen, J. C., Zelman, R., Horwitz, P. A., Bochenek, A., Krauze, A., Grothusen, C., Dudek, D., Heyrich, G., Kolh, P., Legrand, V., Coelho, P., Ensminger, S., Nasseri, B., Ingemansson, R., Olivecrona, G., Escaned, J., Guera, R., Berti, S., Chieffo, A., Burke, N., Mooney, M., Spolaor, A., Hagl, C., Nabauer, M., Suttorp, M. J., Stine, R. A., Mcgarry, T., Lucas, S., Endresen, K., Taussig, A., Accola, K., Canosi, U., Horvath, I., Cannon, L., Talbott, J. D., Akins, C. W., Kramer, R., Aschermann, M., Killinger, W., Narbute, I., Burzotta, Francesco, Bogers, A., Zijlstra, F., Eltchaninoff, H., Berland, J., Stefanini, G., Cruz Gonzalez, I., Hoppe, U., Kiesz, S., Gora, B., Ahlsson, A., Corbascio, M., Bilfinger, T., Carrie, D., Tchetche, D., Hauptman, K. -E., Stahle, E., James, S., Sandner, S., Laufer, G., Lang, I., Witkowski, A., Thourani, V., Suryapranata, H., Redwood, S., Knight, C., Maccarthy, P., de Belder, A., Banning, A., Gershlick, A., Sabate M. (ORCID:0000-0001-6635-4985), Berg G., Laine M., and Burzotta F. (ORCID:0000-0002-6569-9401)

Abstract

Background: The Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) trial was a non-inferiority trial that compared percutaneous coronary intervention (PCI) using first-generation paclitaxel-eluting stents with coronary artery bypass grafting (CABG) in patients with de-novo three-vessel and left main coronary artery disease, and reported results up to 5 years. We now report 10-year all-cause death results. Methods: The SYNTAX Extended Survival (SYNTAXES) study is an investigator-driven extension of follow-up of a multicentre, randomised controlled trial done in 85 hospitals across 18 North American and European countries. Patients with de-novo three-vessel and left main coronary artery disease were randomly assigned (1:1) to the PCI group or CABG group. Patients with a history of PCI or CABG, acute myocardial infarction, or an indication for concomitant cardiac surgery were excluded. The primary endpoint of the SYNTAXES study was 10-year all-cause death, which was assessed according to the intention-to-treat principle. Prespecified subgroup analyses were performed according to the presence or absence of left main coronary artery disease and diabetes, and according to coronary complexity defined by core laboratory SYNTAX score tertiles. This study is registered with ClinicalTrials.gov, NCT03417050. Findings: From March, 2005, to April, 2007, 1800 patients were randomly assigned to the PCI (n=903) or CABG (n=897) group. Vital status information at 10 years was complete for 841 (93%) patients in the PCI group and 848 (95%) patients in the CABG group. At 10 years, 244 (27%) patients had died after PCI and 211 (24%) after CABG (hazard ratio 1·17 [95% CI 0·97–1·41], p=0·092). Among patients with three-vessel disease, 151 (28%) of 546 had died after PCI versus 113 (21%) of 549 after CABG (hazard ratio 1·41 [95% CI 1·10–1·80]), and among patients with left main coronary artery disease, 93 (26%) of 357 had died after PCI versus 98 (28%) of 348 after CABG (0·90 [0·68–

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results